ATOSSA GENETICS INC
NASDAQ: ATOS (Atossa Therapeutics, Inc.)
Last update: yesterday, 6:29AM0.763
0.01 (1.17%)
| Previous Close | 0.754 |
| Open | 0.770 |
| Volume | 299,883 |
| Avg. Volume (3M) | 1,118,579 |
| Market Cap | 98,544,552 |
| Price / Book | 1.70 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 - 15 Aug 2025 |
| Diluted EPS (TTM) | -0.200 |
| Current Ratio (MRQ) | 12.67 |
| Operating Cash Flow (TTM) | -22.29 M |
| Levered Free Cash Flow (TTM) | -15.54 M |
| Return on Assets (TTM) | -21.67% |
| Return on Equity (TTM) | -34.87% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Atossa Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -0.38 |
|
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.07% |
| % Held by Institutions | 26.58% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Y-Intercept (Hong Kong) Ltd | 30 Jun 2025 | 386,334 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 7.50 (Ascendiant Capital, 883.09%) | Buy |
| Median | 5.75 (653.70%) | |
| Low | 4.00 (Craig-Hallum, 424.32%) | Buy |
| Average | 5.75 (653.70%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 0.880 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Ascendiant Capital | 06 Jun 2025 | 7.50 (883.09%) | Buy | 0.900 |
| Craig-Hallum | 05 Jun 2025 | 4.00 (424.32%) | Buy | 0.860 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |